40. Approaches to immunology, inflammation, and oncology, Dr. Luisa Salter-Cid, CSO, Gossamer Bio
Dr. Salter-Cid brings to Gossamer Bio over 20 years of drug discovery experience in the biotech and pharmaceutical industries and spent the last 13 years at Bristol Myers Squibb (“BMS”) in increasing ...
6 Tammi 202129min
39. Biotech2050 Season 1 Wrap Up: Co-Hosts, Alok Tayi and Rahul Chaturvedi
Thank you for your support for Season 1! We reflect and look forward to Season 2 on this episode! Learn more about our co-hosts below! Alok Tayi is the Vice President of Life Sciences at Egnyte where...
16 Joulu 202010min
38. AI-driven early detection cancer screening from a blood test, Ken Chahine, CEO, Helio Health
As Executive Vice President and General Manager of Ancestry.com, a 1.6 billion dollar technology company, Ken led the launch of AncestryDNA, a large-scale e-commerce genetic genealogy test with revenu...
11 Marras 202022min
37. Bringing new treatments to psychiatric orphan diseases, Ibs Mahmood, CEO, AMO Pharma
Ibraheem Mahmood has an extensive life science and finance background that spans more than 20 years. His experience includes previous roles in Lifescience M&A and Fundraising at Nomura, Lifescience Eq...
4 Marras 202023min
36. Harnessing the innate immune system to combat disease, RJ Tesi, CEO and CMO, INmune Bio
Dr. Raymond J. Tesi has been President, Chief Executive Officer and acting Chief Medical Officer since the formation of INmune Bio in September 2015. From November 2011 to May 2015, Dr. Tesi was CEO, ...
28 Loka 202024min
35. Continuous manufacturing in drug development, Matthew Bio, CEO, Snapdragon Chemistry
Dr. Matthew Bio is President & CEO at Snapdragon Chemistry. Matthew began his career in chemistry more than 20 years ago developing continuous processes for the manufacture and purification of acryla...
21 Loka 202027min
34. Automation and Regenerative Manufacturing, Alexander Titus, Chief Strategy Officer, ARMI
Alexander Titus is the Founder of Bioeconomy.XYZ and the Chief Strategy Officer (CSO) at the Advanced Regenerative Manufacturing Institute (ARMI), where his career focuses on the intersection of techn...
14 Loka 202030min
33. RNA modification gene therapy for rare disorders, Jim Burns, CEO, Kathie Bishop, CSO, Locanabio
James Burns, PhD, Chief Executive Officer, Locanabio James (Jim) Burns, Ph.D., joined Locanabio in December 2019 as CEO and Board member. Prior to joining Locanabio, Dr. Burns served as the CEO of Ca...
7 Loka 202027min
